SFY 2019 - 2020 MC MLR Report Summary
HIV SNP line of business
- Report also available in Portable Document Format (PDF)
| SFY 2019 - 2020 MC MLR Report Summary | |||||||
|---|---|---|---|---|---|---|---|
| HIV SNP line of business | |||||||
| Plan | MLR AFTER Credibility Adjustment |
Medical Expense (Total Numerator) |
Premium (Total Denominator) |
Remittance | Credible | MMs | |
| Amida Care Inc. | 93.41% | $405,754,577 | $444,511,959 | $0 | Partially Credible | 88,904 | |
| MetroPlus Health Plan, Inc | 96.03% | $201,529,688 | $216,402,912 | $0 | Partially Credible | 48,061 | |
| VNS (d/b/a VNSNY Choice) and Subsidiary | 94.15% | $174,718,758 | $192,633,514 | $0 | Partially Credible | 36,105 | |
| Total | $782,003,023 | $853,548,385 | $0 | 173,070 | |||
NOTES:
Please note that the Remittance is for this line of business for one year ONLY based on a MLR Target of 86%.
No remittance for plan if Non-Credible
